E-Health solutions provider Orion Health Group Ltd (ASX: OHE) has been on a tear in the past month, following a number of major contract announcements in quick succession.

On 30 March, Orion announced a contract with a major US health insurer. While financial specifics were not provided, if we use the number of patient records Orion manages as a proxy, then the announcement for 3 million patients represented an increase of around 3% on the company’s previous total of 90 million records.

On 6 April, Orion announced it had won a contract with Metro North, the largest health service in Queensland, to provide its Referrals Management software platform. Metro North serves 900,000 people, and Orion believes the company could be convinced to subscribe to additional services from Orion in the future.

Just this morning, Orion announced yet another deal, this time with health providers in England and Scotland. Orion will provide integrated solutions to two leading hospitals in London, as well as an integrated solution for National Health Service (NHS) centre in Fife, in Scotland. The London hospitals serve over 1 million people, while NHS Fife serves 360,000.

Productivity in health management

The type of software provided by Orion reduces the people-management burden at hospitals and, can be an effective and cheap way to boost productivity while also improving the quality of patient care. The benefits to Orion include regular income through its fee-based subscription model, as well as relative customer stickiness due to the difficulty of selecting an alternative provider.

Another company easing the burden on medical professionals, this time in the field of radiology, is Pro Medicus Limited (ASX: PME), which has also soared in recent weeks thanks to a number of contract wins in the US. While neither company looks particularly cheap on conventional valuation metrics, investors must look beyond price to the potential growth that lies ahead. Orion is still a loss-making business, but it is well diversified and recent contracts give it a good platform from which to bid for more customers.

Before buying Orion Health however, I'd take a closer look at The Motley Fool's  3 Best Dividend Buys Nowrecently selected by dividend investing guru Andrew Page for their income and growth potential. Unfortunately, if you're reading this message, that means you're not on the list to uncover their names before they potentially go gangbusters!

You can change that by signing up for our free Take Stock email service - bringing you the latest and greatest in market news every week. Just click here and enter your email address - and as a bonus we'll see you Andrew's full report on his 3 Best Dividend Buys Now.

It's completely free - what are you waiting for?

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.